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General Introduction 
 4 
In veterinary clinical practice, alkaline phosphatase (ALP) is very important in 
blood biochemical examinations as an indicator of canine hepatobiliary diseases. ALP is 
a membrane-associated enzyme present in various tissues (Hoffmann and Dorner, 1975). 
In dogs, only 3 ALP isoenzymes, liver, bone, and corticosteroid-induced ALP can be 
detected in the serum because the other ALP isoenzymes have very short half-lives 
(Hoffmann and Dorner, 1977). The liver ALP (LALP) is produced in the liver and 
accounts for the highest isoenzyme percentage in normal canine serum (Ruegnitz and 
Schwartz, 1971). Bone ALP (BALP) is produced in actively growing bone (Fishman, 
1990) while the corticosteroid-induced ALP (CALP) is produced in the liver and induced 
by endogenous and exogenous corticoid hormone stimulation (Eckersall and Nash, 1983; 
Wellman et al., 1982). CALP is a unique isoenzyme of dogs, and has little or no activity 
in the serum of clinically healthy dogs (Dorner et al., 1974). However, its function and 
mechanism of production is not well known. It was confirmed that experimental 
administration of corticosteroid to dogs increased the serum CALP activity and 
hepatocyte vacuolation secondary to glycogen accumulation (Syakalima et al., 1997a; 
Wiedmeyer et al., 2002). Although a few studies have reported that serum CALP was 
detected in dogs with hepatobiliary diseases, its actual activity or percentage was not 
reported (Syakalima et al., 1997b; Wilson et al., 1992). Therefore, the relationship 
between serum CALP levels and hepatobiliary diseases is still unclear, and studies on the 
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clinical utility of serum CALP levels are inadequate.  
 In dogs, hepatocyte vacuolation is believed to occur as a result of excess 
accumulation of glycogen, lipid, water, or intracellular edema (Guilford W.G. Center, 
1996; Rothuizen, 2006) and frequently associated with high serum ALP activity (Dorner 
et al., 1974; Rogers and Ruebner, 1977; Sanecki et al., 1987). Canine hepatocyte 
vacuolation caused by excess glycogen accumulation, which is induced by endogenous or 
exogenous glucocorticoid (Fittschen and Bellamy, 1984; Syakalima et al., 1997a). In 
Scottish Terriers, various endogenous steroid hormones were reported to be associated 
with vacuolar hepatopathy and high serum ALP activity (Zimmerman et al., 2010) and 
hepatocellular carcinoma associated with vacuolar hepatopathy has been reported 
(Cortright et al., 2014).  
On the other hand, hepatocyte vacuolation caused by excess lipid accumulation 
was reported in dogs with congenital portosystemic shunt (Hunt et al., 2013; Lee et al., 
2011) and nodular hyperplasia (Fabry et al., 1982). Hepatocyte vacuolation caused by 
lipid and glycogen accumulation accompanied by hyperlipidemia and increased plasma 
ALP activity was also reported in Schnauzers (Guilford W.G. Center, 1996). Although 
canine hepatocyte vacuolation is induced by multiple factors, the relationship between 
ALP isoenzyme activity and causative substances of hepatic vacuolation has not been 
thoroughly investigated. Excess hepatic lipid accumulation is referred to as fatty liver in 
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other species (Anstee and Goldin, 2006; Arslan, 2014; Musso et al., 2009). In humans, 
fatty liver is a confirmed clinical condition, which progresses to hepatitis, cirrhosis, and 
hepatocellular carcinoma (Dietrich and Hellerbrand, 2014; Musso et al., 2009). In 
addition, gene expression associated with hepatic lipid metabolism and serum 
biochemical characterization have been well-studied in this condition (Arslan, 2014; 
Dietrich and Hellerbrand, 2014; Kikuchi et al., 2014). Therefore, canine hepatic lipid 
accumulation is considered a useful fatty liver animal model; however, little is known 
about the mechanism and clinicopathological effect of hepatic lipid accumulation in dogs.  
 Therefore, the studies conducted for this thesis were carried out to investigate 
the relationship between the activity of serum ALP isoenzymes and the pathological 
features of hepatic lipid accumulation in dogs with hepatobiliary diseases. The study 
described in Chapter 1 of this thesis was aimed at clarifying the relationship between 
serum ALP isoenzyme activities and hepatobiliary diseases in dogs without a history of 
glucocorticoid drug administration. In chapter 2, the actual lipid or glycogen amount in 
the liver was measured and compared to serum ALP isoenzyme activity and hepatic 
vacuolation severity in dogs with hepatobiliary diseases. In addition, the expression of 
lipid metabolism-associated genes in the liver tissue was analyzed. In Chapter 3, hepatic 
lipid accumulation was experimentally induced in dogs by intravenous administration of  
fat emulsion, and the change in the serum activity of each ALP isoenzyme was evaluated. 
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In addition, the expression of lipid metabolism-associated genes and each ALP 
isoenzyme gene in the liver was analyzed. These studies were aimed at assessing the 
clinical significance of serum CALP levels and hepatic lipid accumulation.  
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Chapter 1 
Analysis of alkaline phosphatase isoenzymes 
in dogs with hepatobiliary deseases 
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ABSTRACT 
In dogs, 3 alkalinephosphatase (ALP) isoenzymes, liver ALP (LALP), bone ALP 
(BALP) and corticosteroid-induced ALP (CALP), can be detected in serum. CALP is 
unique ALP isoenzyme of dogs and confirmed to be increased in dogs with 
hyperadrenocorticalism or glucocorticoid drug administration. Although few reports 
showed serum CALP activity was detected in	 dogs with hepatobiliary diseases, the 
actual CALP activity was not shown. The objective of this study is to reveal the 
relationship between canine CALP activity and hepatobiliary diseases, together with 
other factor in dogs without glucocorticoid administration. 
Serum ALP isoenzymes in dogs with hepatobiliary diseases was evaluated 
retrospectively. Dogs had history of glucocorticoid administration was excluded. Serum 
CALP percentage and activity were compared with diagnoses, serum cortisol 
concentration, age, sex, breed and ALT activity. 
Seventy-two dogs with hepatobiliary diseases were analyzed in this study. Serum 
CALP level was increased in dogs with hepatobiliary diseases and serum CALP activitiy 
was significantly increased in chronic hepatitis, hepatocellular adenoma and nodular 
hyperplasia group. No significant correlation was observed between serum cortisol 
concentration and serum CALP percentage or activity. 
Dogs with hepatobiliary disease could show high serum ALP activity because of 
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increasing serum CALP level, even if the dogs have not been administrated 
glucocorticoid drug and the serum cortisol consentration is normal. 
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INTRODUCTION 
In dogs, alkaline phosphatase (ALP) isoenzyme is produced in various tissues 
(liver, bone, kidney, intestine, and placenta) (Dorner et al., 1974; Eckersall and Nash, 
1983; Hoffmann and Dorner, 1975; Wellman et al., 1982). Only three ALP isoenzymes, 
liver ALP (LALP), bone ALP (BALP), and corticosteroid-induced ALP (CALP), can be 
detected in canine serum because of the very short half-lives of other ALP isoenzymes 
(Hoffmann and Dorner, 1977). LALP, which is produced in the liver, is present in the 
highest concentration in normal canine serum (Hoffmann and Dorner, 1975). BALP is an 
isoenzyme produced in actively dividing bone tissue. Usually, it is not detected in canine 
serum except in puppies, dogs with bone fractures, or bone neoplasms, such as 
osteosarcoma (Ehrhart et al., 1998; Fishman, 1990; Syakalima et al., 1997b). CALP, 
which is produced in the liver and is induced by endogenous or exogenous corticoid 
hormone stimulation (Eckersall and Nash, 1983; Hoffmann and Dorner, 1975; Wellman 
et al., 1982) is unique to dogs (Dorner et al., 1974). However, little is known about the 
detailed mechanism of CALP production. 
The activities of each ALP isoenzyme in canine serum had been calculated by 
measuring the differences in sensitivity against heat (Farley et al., 1994; Hoffmann and 
Dorner, 1975; Saini and Saini, 1978; Teske et al., 1986) or chemical inactivation 
(Mahaffey and Lago, 1991; Ruegnitz and Schwartz, 1971) between each isoenzyme. 
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Although these biochemical methods provide direct result of ALP isoenzyme activities, 
the effect of these inactivation is overlapped between each ALP isoenzymes (Dorner et 
al., 1974; Syakalima et al., 1997b; Teske et al., 1986). The overlap makes it difficult to 
distinguish clearly between the ALP isoenzyme activities by biochemical methods. 
Alternatively, electrophoresis has been widely used to discriminate between different 
ALP isoenzymes (Hatayama et al., 2011; Itoh et al., 2002). 
CALP activity was increased in dogs that received experimental administration 
of corticosteroid (Syakalima et al., 1997a; Wiedmeyer et al., 2002) and dogs with 
spontaneous hyperadrenocorticism (Teske et al., 1989; Wellman et al., 1982). In Scottish 
Terriers, endogenous hormones (cortisol, estradiol, androstenedioneandrostendione, 
progesterone, aldosterone, and 17α-hydroxyprogesterone) and aging have also been 
reported to relate with high serum ALP activity (Cortright et al., 2014; Gallagher et al., 
2006; Nestor et al., 2006; Zimmerman et al., 2010).  
In clinical practice, serum hepatic enzymes such as ALP and ALT are widely 
evaluated as part of diagnostic evaluation of hepatobiliary diseases. Few studies have 
measured canine serum CALP levels in hepatobiliary cases. In these reports, a certain 
number of dogs with hepatobiliary diseases including cirrhosis, liver tumor (Syakalima et 
al., 1997b), portosystemic shunt, chronic hepatitis, hepatocellular carcinoma, hepatoma, 
and phenobarbital-related vacuolar hepatopathy (Wilson et al., 1992) had increased 
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CALP activities. However, these studies used the chemical inactivation method to 
determine CALP activities and the numbers of dogs used were too small to determine the 
differences between each hepatobiliary disease. Another report showed that serum CALP 
was detected in dogs with hepatocellular injury, but the number of dogs in the study was 
small and CALP activity in each case was not shown (Kidney and Jackson, 1988).  
The purpose of the present study is to clarify the relationship between canine 
ALP isoenzyme activities and hepatobiliary diseases, as well as serum cortisol 
concentration, age, sex, breed, and ALT activity. 
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MATERIALS AND METHODS 
Clinical Cases  
The Medical records of dogs referred to the Veterinary Medical Center of the 
University of Tokyo from April 2012 to March 2014 were reviewed retrospectively. The 
following inclusion criteria were used: (1) confirmed diagnoses of hepatobiliary disease 
and (2) complete history, signalment (age, sex, and breed), and clinicopathological data 
(ALP isoenzymes and ALT activity, percentage of each ALP isoenzymes). Dogs treated 
with a glucocorticoid drug within 6 months before their first visit were excluded from this 
study. Seven clinically healthy laboratory beagles were assigned as normal controls for 
assessment of serum ALP isoenzyme and ALT activities. 
 
Analyses of ALP isoenzymes, ALT, and Cortisol 
The activity of total ALP was measured using the p-nitrophenylphosphate 
assay (reference range: 47-237 U/L). Agarose gel electrophoresis was performed for 
serum to separate each ALP isoenzyme. ALP staining was performed using 
5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) and the 
density of each band was measured (Itoh et al., 2002). Activity of each ALP isoenzyme 
was calculated from the ratio of densitometry and total ALP activity (LSI Medience, 
Tokyo, Japan). Serum cortisol concentration was measured (Monolis, Inc. Tokyo, Japan) 
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without ACTH stimulation test. The plasma ALT activity was measured by automatic 
blood chemistry measurement equipment (DRI-CHEM, Fujifilm Medical Co., Japan, 
reference range: 17-78). 
 
Statistical Analysis 
Statistical analyses were conducted using the JMP Pro 11 software (SAS 
Institute, Cary, North Carolina, United States). Statistical analyses were performed for 
groups that include more than 2 dogs. The Steel test was used to test for significant 
differences in total ALP activity, CALP percentage, and CALP activity between the 
control dogs and dogs with hepatobiliary diseases. Spearman’s rank correlation was used 
for correlation analysis between cortisol concentration and CALP activity or CALP 
percentage, age, and CALP activity or CALP percentage. Wilcoxon rank sum test was 
used to test for significant differences in age between the portosystemic shunt group and 
other hepatobiliary disease groups. The Steel-Dwass test was used to test for significant 
differences in CALP percentage and CALP activity in sex or breeds groups. P < 0.05 was 
considered significant for the remaining statistical analysis in the present study. 
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RESULTS 
Signalment 
According to the inclusion criteria, 103 dogs were recruited in the present study. 
Thirty-one dogs were excluded because of a history of glucocorticoid administration, thus, 
72 dogs were included in this study. The population of each diagnosis was as follows: 
portosystemic shunt (PSS, n=26), chronic hepatitis (CH, n=17), hepatocellular carcinoma 
(HCC, n=7), hepatocellular adenoma (HCA, n=6), nodular hyperplasia (NH, n=5), 
vacuolar hepatopathy (VH, n=3), hepatic abscess (HA, n=1), and gallbladder mucocele 
(GM, n=7). The summary of clinicopathological data in each diagnostic group is shown 
in Table1. Dogs with hepatobiliary diseases included 30 male (neutered, 15) and 42 
female (neutered, 28). The median age of the dogs with hepatobiliary disease was 8.3 
years (range 0.4-14.1 years). Dogs with PSS (median age 2.4 years, range 0.4-8.9 years) 
were significantly younger than dogs with other hepatobiliary diseases (median age 9.63 
years, range 3.0-14.1 years) (P < 0.001). A significant difference in total ALP activity 
was observed between control group and dogs with CH (P = 0.0012), HCC (P = 0.0128), 
HCA (P = 0.0196) and NH (P = 0.0321) group, respectively. There was a significant 
difference of ALT activity between the control group and dogs with CH (P = 0.0145) and 
HCA (P = 0.413) groups. Breeds of the dogs with hepatobiliary diseases were as follows: 
Toy poodle (n=10), Chihuahua (n = 6), Yorkshire Terrier (n = 5), Miniature Schnauzer 
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(n=5), Labrador Retriever (n=4), Shih Tzu (n=3), Italian Greyhound (n=3), and others 
(n= 34).  
Analysis of ALP isoenzymes 
Activity of total ALP, LALP, CALP and BALP were calculated in 79 dogs 
(hepatobiliary diseases group n=72, control group n=7). None of 79 dogs had BALP. 
Both LALP and CALP were detected in 77 of 79 dogs in various proportions. CALP was 
not detected in 2 dogs.  
The median of CALP percentage in the control group was 6.8% (range, 
0-12.1%) (Figure 1A). Sixteen of 72 (22.2%) cases had CALP percentage > 50%. The 
number of dogs with CALP percentage higher than 50% were as follows: PSS (1/26 
[3.8%]), CH (2/17 [11.8%]), HCC (1/7 [14.3%]), HCA (3/6 [50%]), NH (2/5 [40%]), VH 
(3/3 [100%]), HA (0/1 [0%]) and GM (3/7 [42.9%]). There was no significant difference 
in CALP percentage between controls and any diagnosis group. The median of CALP 
activity in the control group was 18 U/L (range, 0-28 U/L) (Figure 1B). There was a 
significant difference in CALP activity between control group and CH (P = 0.0038), 
HCA (P = 0.0198) and NH (P = 0.0332) group. 
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Serum cortisol concentration was measured in 42 dogs with hepatobiliary 
diseases. Of these, 33 of 42 dogs (78.6%) showed a lower serum cortisol concentration 
than the reference value (7.8µg/dL), while 8 (19.0%) had concentrations above the 
reference value (Figure 2). The number of dogs with high serum cortisol concentrations 
was as follows: PSS (1/18 [5.2%]), CH (4/6 [66.7%]), HCC (1/7 [14.2%]), HCA (1/6 
[16.7%]), NH (1/2 [50%]), and GM (0/3 [0%]). Serum cortisol concentration was not 
measured in the HA and VH groups. Serum cortisol concentration was not significantly 
correlated with CALP percentage (r = 0.17, P = 0.25) and CALP activity (r = 0.04, P = 
0.58). 
The relationships between age and CALP percentage and activity are shown in 
Figure 3. There was a weak correlation between age and CALP percentage (r = 0.32, P = 
0.008). A moderate correlation between age and CALP activity was found (r = 0.54, P < 
0.001). There non-significant correlation between ALT activity and CALP percentage (r 
= -0.10, P = 0.34) or CALP activity (r = 0.19, P = 0.12) (data not shown). No significant 
difference in CALP percentage or CALP activity was observed in any breed or sex group 
(data not shown). 
 19 
DISCUSSION 
This is the first report in which serum CALP isoenzyme was analysed with 
serum cortisol concentration, signalment, and ALT activity in canine hepatobiliary 
disease groups. In this study, I reviewed 72 dogs with hepatobiliary diseases that had not 
been administered corticosteroid drugs. CALP levels were higher in dogs with various 
hepatobiliary diagnoses, especially those with CH, HCA, and NH. 
In the present study, CALP percentage and CALP activity did not show a 
significant correlation with serum cortisol concentrations. This result suggests that 
cortisol is not the only potential underlying mechanism for high serum CALP percentage 
and activity. In Scottish Terriers, various serum corticosteroid hormones (cortisol, 
androstenedione, estradiol, progesterone, 17α-hydroxyprogesterone, and aldosterone) 
were reported to be increased in cases with high serum ALP activity (Cortright et al., 
2014; Zimmerman et al., 2010). Other studies showed that dogs suspected as 
hyperadenocorticism had a normal cortisol concentration in serum after an ACTH 
stimulation test. The dogs also showed elevated sex hormone concentrations 
(androstenedione, estradiol, progesterone (Syme et al., 2001), and 
17α-hydroxyprogesterone (Ristic et al., 2002; Syme et al., 2001)) after an ACTH 
stimulation test. Some of these dogs had higher sex hormone concentrations than the 
reference range at baseline even before the ACTH stimulation test. In this study, I did not 
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carry out measurement of the serum sex hormone concentrations with an ACTH 
stimulation test, so endogenous sex hormones and potential hyperadrenocorticism might 
be a candidate to induce serum CALP in dogs with hepatobiliary diseases. Because serum 
cortisol concentration was measured only once in this study, it is possible that a circadian 
fluctuation of cortisol (Murase et al., 1988; Palazzolo and Quadri, 1987) would influence 
serum CALP level. 
In this study, dogs with CH showed significantly higher serum CALP activity. 
Serum cortisol of 4 of 6 dogs with CH exceeded the reference range. In a previous report, 
20 of 59 dogs with non-adrenal disease showed higher baseline cortisol concentrations 
than the reference range and while only 8 of the 59 dogs with non-adrenal disease had 
serum cortisol concentration higher than the reference range after an ACTH stimulation 
test (Kaplan et al., 1995). Dogs with CH in this study also might have a high baseline 
serum cortisol concentration, and CALP activity may be increased in response to this 
serum cortisol increase. The number of dogs in the CH group in which serum cortisol was 
measured was small in this study, so a larger scale study would be needed to reveal the 
relationship between CALP and cortisol in CH dogs. 
Dogs with HCA and NH also showed a significantly higher serum CALP 
activity in this study. One dog with each disease had serum cortisol concentrations that 
exceeded the reference range, suggesting that the increase of CALP activity in dogs with 
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HCA and NH are related to serum cortisol. Another possible explanation for the CALP 
increase is that CALP may be produced in tumours and hyperplasia of liver since CALP 
isoenzyme is produced in liver tissue (Sanecki et al., 1987). To clarify the relationship 
between CALP increase and HCA and NH, studies are needed to investigate whether 
there is a difference of CALP isoenzyme activity or expression between affected and 
non-affected areas of the liver in HCA and NH dogs. 
There was a moderate correlation between CALP activity and age in dogs with 
hepatobiliary diseases. However, dogs in PSS group were significantly younger than dogs 
in other hepatobiliary groups and the increase of serum CALP activity in the PSS group 
was not significant (data not shown). There was no significant difference between CALP 
levels and age when dogs with PSS were excluded from the hepatobiliary disease group. 
Therefore, differences in age in each disease group may have influenced the relationship 
between age and CALP activity. 
In conclusion, the present study suggests that specific hepatobiliary diseases 
relate to high serum CALP percentage and activity without the administration of a 
glucocorticoid drug. Since I did not study the mechanism of the relationship between 
CALP increase and each factor in this study, additional investigations including the 
measurement of serum corticosteroid hormones are necessary to determine the direct 
cause of high CALP activity in dogs with hepatobiliary diseases.  
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Table 1. Summary of diagnoses and clinical data of dogs with hepatobiliary disease 
Category n 
male (neutured) / 
female(neutured) 
Median age (y) (range) Total ALP (U/L) ALT (U/L) 
Control 7 5(3) / 2(2) 4.8 (3.3-7.2) 177 (106-230) 56 (22-74) 
PSS 26 10(2) / 16(8) 2.4 (0.4-8.9) 304 (70-1816) 131 (43-1743) 
CH 17 8(3) / 9(5) 8.8 (3.0-14.1) 1143 (336-7416)* 488 (65-1495)* 
HCC 7 3(3) / 4(4) 11.5 (6.6-12.9) 1581 (383-15070)* 417 (62-1025) 
HCA 6 4(4) / 2(1) 8.9 (7.5-12.0) 2464 (1017-19281)* 494 (287-562)* 
NH 5 1(0) / 4(4) 9.2 (8.0-13.8) 1182 (374-3918)* 143 (36-284) 
HA 1 0(0) / 1(1) 16.8 440 148 
VH 3 1(1) / 2(1) 9.0 (6.3-10.3) 2635 (1381-15322) 156 (98-215) 
GM 7 3(2) / 4 (4) 10.4 (4.1-12.8) 2948 (117-11089) 194 (45-1156) 
PSS: portosystemic shunt, CH: chronic hepatitis, HCC: hepatocellular carcinoma, HCA: hepatocellular adenoma, 
NH: nodular hyperplasia,HA; hepatic abscess,  VH: vacuolar vepatopathy, GM: gallbladder mucocele 
*:significant difference between control group 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dot plot of (A) serum CALP percentage and (B) serum CALP activity of each diagnosis. 
PSS: portsystemic shunt, CH: chronic hepatitis, HCC: hepatocellular carcinoma, HCA: 
hepatocellular adenoma, NH: nodular hyperplasia, VH: vacuolar hepatopathy, GM: 
gallbladder mucocele. One dog in control group and one dog in PSS group showed 0 
(U/L) in CALP activity. So, the results of these 2 dogs are not drawn in Figure 1B.  
＊CALP activity in dogs with hepatobiliary disease is significantly (P < 0.05) increased, 
compared with CALP activity in control dogs. Cc 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scatter plot of serum CALP percentage (A) and CALP activity (B) and cortisol 
concentration in 43 dogs with hepatobiliary disease. Dot line shows upper limit of 
reference range in serum cortisol. 
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scatter plot of (A) CALP percentage and age, (B) CALP activity and age in 72 dogs with 
hepatobiliary disease. 
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ABSTRACT 
Vacuolation is a common hepatic histological change in dogs. Accumulation of 
lipid and glycogen is believed to be the cause of hepatocyte vacuolation, but the 
relationship between vacuolation and the actual amount of glycogen and lipid in the 
canine liver has not been clarified yet. The aim of this study is to quantify lipid and 
glycogen accumulation in canine liver and compare them with vacuolation severity, 
blood biochemical parameters, and body conditioning score.  
Liver tissue samples were taken prospectively from dogs with suspected 
hepatobiliary diseases. Lipid accumulation of the liver was analyzed by calculating the 
percentage of lipid area in Oil red O stained frozen sections. Glycogen amount was 
quantified by a colorimetric method. Lipid and glycogen accumulation in the liver was 
compared between each diagnosis, histological vacuolar severity score blood chemistry 
profile and ALP isoenzyme, body conditioning score and history of glucocorticoid drug 
administration. Relative expression of 8 lipid metabolism-associated genes (SREBP1c, 
PPARα, PPARγ, ChREBP1, LPL, LFABP, DGAT1 and DGAT2) in liver tissue was 
quantified by real time RT-PCR. 
Percentage of lipid area was evaluated in 58 dogs and glycogen weight was 
measured in 54 dogs in this study. The percentage of lipid area was significantly higher in 
the liver of chronic hepatitis group and non-neoplastic area of hepatocellular carcinoma 
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group than healthy control group. In dogs with non-neoplastic diseases, dogs with more 
lipid accumulation than control showed higher corticosteroid-induced ALP (CALP) 
percentage and activity than dogs with normal lipid accumulation groups. Glycogen 
weight in liver was not significantly elevated in any of the disease group and was 
unrelated to history of glucocorticoid drug administration. No relation was observed 
between lipid or glycogen accumulation and the respective vacuolation severity scores. 
Plasma concentration of triglyceride had significant and moderate correlation with 
percentage of lipid area in dogs with non-neoplastic liver diseases, while other blood 
biochemical parameters were not related to liver accumulation of lipid nor glycogen. 
Expression of lipoprotein lipase (LPL), which induce lipolytic pathway, was elevated in 
dogs with high level of hepatic lipid accumulation, but not in dogs with normal level of 
hepatic lipid accumulation. Both groups of dogs with high and normal level of lipid 
accumulation showed high expression of PPARγ and DGAT1, which are lipid synthesis 
associated genes, when compared to normal control dogs.  
This study revealed that there is a number of excess lipid accumulation in dogs 
with hepatobiliary diseases. The result of this study suggests that excess hepatic lipid 
accumulation would be a new cause of increased serum CALP level and increased 
lipogenesis would cause excess lipid accumulation in liver of dogs with hepatobiliary 
diseases.
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INTRODUCTION 
Hepatocyte vacuolation is a common hepatic histopathological finding in dog 
with various diseases (Sepesy et al., 2006).  In the HE stained liver section with 
hepatocyte vacuolation, enlarged hepatocytes with formation of cytoplasmic spaces are 
observed (Guilford W.G. Center, 1996; Sepesy et al., 2006), which is considered to be the 
result of excess accumulation of glycogen, lipid and water in the cytoplasm, or 
intracellular edema (Guilford W.G. Center, 1996; Rothuizen, 2006). Even though 
hepatocyte vacuoleation has been widely known, the clinical importance has not been 
clarified yet. 
Hepatocyte vacuolation in dogs has been considered to relate with steroid 
hormones and often accompanied with high serum ALP activity, though the mechanism 
is not clear. Dogs with hyperadrenocorticism, which is characterized by endogenous 
glucocorticoid excess, often have vacuolar hepatopathy (VH) (Rogers and Ruebner, 
1977; Sepesy et al., 2006). Scottish Terriers are known to have a predilection to develop 
VH associated with endogenous sex hormones, high production of steroid hormones in 
adrenal grand, together with characteristic high serum ALP activity (Cortright et al., 
2014; Zimmerman et al., 2010). Experimental glucocorticoid administration also induced 
glycogen accumulation in canine liver (Fittschen and Bellamy, 1984), dose-dependent 
hepatic vacuolation and elevation of corticosteroid-induced ALP isoenzyme activity 
 30 
(Syakalima et al., 1997a). On the other hand, moderate or severe VH was observed in 
dogs without history of exogenous glucocorticoid exposure or excess endogenous 
glucocorticoid production (Sepesy et al., 2006). And, although glycogen is believed to be 
the major component of hepatic vacuolation, quantitative analysis on glycogen 
accumulation has not been reported so far. 
 The relation between hepatocyte vacuolation and lipid accumulation has not 
been studied in detail at present, however, several reports have shown the hepatic lipid 
accumulation in dogs. Hepatic vacuolation observed in nodular hyperplasia was stained 
with Oil Red O (ORO) indicating the accumulation of lipid (Fabry et al., 1982). In 
Schnauzer, VH associated with hyperlipidemia were shown to contain both lipid and 
glycogen accompanied with high serum ALP activity (Guilford W.G. Center, 1996). 
Furthermore, excess lipid droplet in hepatocytes was reported in dogs with congenital 
portosystemic shunt (cPSS) evaluated by imaging analysis of ORO stained frozen section 
(Hunt et al., 2014; Hunt et al., 2013). However, hepatic lipid accumulation in dog with 
other hepatobiliary diseases has not been evaluated at present. The relation of lipid 
accumulation and serum ALP activity has also not been clarified yet.  
In other species, fatty liver is caused by hepatic de novo lipogenesis (Anstee and 
Goldin, 2006; Arslan, 2014; Assy et al., 2000). Four transcription factors regulating 
hepatic lipid metabolism include sterol response element binding protein-1c (SREBP-1c), 
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carbohydrate response element binding protein (ChREBP), the peroxisome 
proliferator-activated receptor α (PPAR α) and PPAR γ. These transcription factors 
regulate lipid metabolism-associated genes including lipoprotein lipase (LPL) which 
hydrolysis lipid for uptake in hepatocyte, liver fatty acid binding protein (LFABP) which 
delivery fatty acids in hepatocyte, diacylglycerol acyltransferase (DGAT)1 and DGAT2, 
which catalyzes the final step of triglyceride synthesis.  
The aim of this study is to determine the relationship of lipid and glycogen 
accumulation in the liver with clinical or biochemical features in canine hepatobiliary 
diseases, and to investigate the mechanism of canine hepatic excess lipid accumulation 
with gene expression analysis. 
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MATERIALS AND METHODS 
Cases 
Seventy-two dogs that underwent liver biopsy in the Veterinary Medical Center 
of the University of Tokyo (VMC-UT) between April 2012 and December 2014 were 
included in this prospective study. Seven clinically healthy beagles were assigned as 
control dogs and biopsied the liver. The procedure was conducted in compliance with the 
guidelines of the Animal Care Committee of the Graduate School of Agricultural and 
Life Sciences, the University of Tokyo (approval number P14-924; approved on 2014). 
 
Clinical data collection 
Clinical records including body conditioning score (BCS: 1-5), age, history of 
glucocorticoid drug administration, and blood biochemical data were reviewed. Blood 
biochemical data included serum ALP isoenzyme activity and percentages (LSI 
Medience, Tokyo, Japan), plasma ALT activity, concentration of glucose, albumin, 
ammonia, total cholesterol and triglyceride (DRI-CHEM, Fujifilm Medical Co., Japan). 
 
Sample collection 
All liver biopsy samples were taken by laparotomy. Both neoplastic and 
non-neoplastic samples were taken from dogs with suspected liver tumors. All liver 
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samples were treated and stored in 4 procedures; 10% formalin fixed sections for HE 
staining, frozen with compound gel for ORO staining, frozen directly for glycogen assay 
and frozen in RNAlater solution (Ambion, Austin, TX) for RNA extraction. HE stained 
sections were subjected to histological diagnosis according to the WSAVA’s criteria 
(Rothuizen, 2006). Congenital portosystemic shunt (cPSS) was diagnosed by contrast 
enhanced CT and portography. Gallbladder mucocele (GM) was diagnosed 
macroscopically on surgery. Vacuolar hepatopathy was diagnosed when there was no 
histopathological disorder other than hepatocyte vacuolation. Dogs diagnosed as 
non-hepatobiliary disease were excluded from this study. 
 
Histopathologic evaluation of hepatocyte vacuolation 
Single pathologist who was unaware of the diagnosis of patients evaluated 
hepatocyte vacuolation. Lipid accumulation was determined as discrete clear vacuolation 
(Figure 4A). Glycogen accumulation was identified on the basis of the finding of wispy 
cytosolic vacuolation with central location of cell nuclei (Figure 4B) (Cortright et al., 
2014). The severity of hepatocyte vacuolation was scored from G0 to G3 (G0, or absent = 
0% of hepatocyte vacuolated, G1, or mild <33% of hepatocyte vacuolated, G2 or 
moderate 34-66% of hepatocyte vacuolated, G3, or severe >67% of hepatocyte 
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vacuolated), based on the human non-alcoholic fatty liver disease grading score (Kleiner 
et al., 2005b). Zonal location of hepatocyte vacuolation was evaluated and the 
classification of vacuolar location was as follows: all zone, zone 1 (periportal), zone 2 
(midzornal), zone 3 (perivenous), zone 1~2, zone 2~3 (Sepesy et al., 2006). Zonal 
location was not evaluated in samples of neoplastic area of hepatic tumors.  
 
Quantification of lipid and glycogen accumulation in liver 
The biopsy sample was placed into a Tissue tek container, which was then filled 
with Tissue tek OTC compound gel (Sakura Finetek, Torrance, CA). The samples were 
frozen rapidly, prior to being cut into 6µm slices, and stained for lipid using a standard 
Oil Red O protocol (Hunt et al., 2014; Hunt et al., 2013). The percentage of the area 
occupied by Oil Red O-stained lipid droplets in the liver tissue was calculated using 
Image J software (http://rsbweb.nih.gov/ij/), for 5 separate, randomly selected ×200 fields 
(Liu et al., 2014). Dogs with lipoglanunomas were excluded from this study because the 
lipid accumulation exists other than hepatic parenchymal cell. Glycogen amounts in the 
liver tissue were analyzed by Glycogen Assay Kit (BioVision, Mountain View, CA) 
using OxiRed probe according to manufacturer’s suggestion.  
 
Quantitative Polymerase Chain Reaction Analysis  
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Total RNA was extracted from the liver samples by using RNAspin Mini RNA 
Isolation Kit (GE Healthcare ). The extracted RNA was then treated with DNase I 
(Invitrogen, Carlsbad, CA) and reverse-transcribed with a PrimeScript RT reagent kit 
(Takara Bioscience, Tokyo, Japan) according to the manufacturer’s protocol. Eight lipid 
metabolism associated genes were selected for quantitative analysis: SREBP1c, PPARα, 
PPARγ, ChREBP1, LPL, LFABP, DGAT1 and DGAT2. Three genes, HMBS, RPL13A and 
RPL32, were included as internal controls. Gene expression was quantified in triplicate 
samples using the Thermal Cycler Dice Real-Time System (Takara Bio Inc, Tokyo, 
Japan) with THUNDERBIRD SYBR qPCR Mix (Toyobo Co. Ltd, Osaka, Japan) 
according to the manufacturer’s instructions. Primers were designed using Primer 3 
(http://primer3.sourceforge.net/) or were selected by referring to previous 
publications(Peters et al., 2007). The sequences of the primer pairs used are shown in 
Table 2. 
The threshold cycle (Ct value) was determined using the second derivative 
maximum method. Before the samples were quantified, standard curves of the relative 
starting amount versus the Ct value were constructed using pooled liver cDNA. The 
amplification efficiency of each reaction was within 80% to 120%. The dissociation 
curve was confirmed to have a single peak in each experiment. Moreover, the PCR 
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products were confirmed to be in agreement with their theoretic sizes by using agarose 
gel electrophoresis. The quantity of each transcript was determined by comparing to the 
mean expression level of HMBS, RPL13A, and RPL32 and represented as relative value 
assuming the mean expression level of healthy control dogs as 1. 
 
Statistical analysis 
Statistical analyses were conducted using the JMP Pro 11 software (SAS 
Institute, Cary, North Carolina, United States). Statistical analyses were performed for 
groups that include more than 2 dogs. Steel test was used to test significant differences in 
percentage of lipid area and glycogen weight between control dogs and dogs with 
hepatobiliary diseases. Steel-Dwass test was used to test for significant differences in 
percentage of lipid area and glycogen weight between each group of vacuolation severity 
score. Spearman’s rank correlation was used for correlation analysis between lipid area 
percentage or glycogen weight and ALP isoenzyme activity, ALP isoenzyme percentage, 
plasma ALT activety, plasma concentration of glucose, albumin, ammonia total 
cholesterol and triglyceride. Wilcoxon rank sum test was used to test for significant 
differences in glycogen weight of the liver between dogs with or without history of 
glucocorticoid drug groups, expression of lipid metabolism associated genes between 
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each group of diagnosis, normal and excess lipid accumulation groups and serum CALP 
activity and percentage between normal and excess lipid accumulation groups. P < 0.05 
was considered significant in the present study. 
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RESULTS 
Clinical cases with heaptobiliary diseases 
Seventy-two dogs underwent liver biopsy in the VMC-UT between April 2012 
and December 2014. Six dogs were excluded because the diagnoses were cancer or 
adenoma that derived from non-hepatic tissue. Eight dogs were excluded because 
lipogranulomas were found in ORO staining sections. These exclusions left 58 dogs in 
the study, and the dogs were grouped according to diagnoses: congenital portosystemic 
shunt (cPSS, n=19), chronic hepatitis and cholangiohepatitis (CH, n=14), vacuolar 
hepatopathy (VH, n=3), hepatocellular carcinoma (HCC, n=9), hepatocellular adenoma 
(HCA, n=8), cholangiocarcinoma (CC, n=1) and gallbladder mucocele (GM,n=4). All of 
dogs with cPSS were also histopathologically diagnosed as intercurrent primary portal 
vein hypoplasia (PHPV). Three of four dogs with GM were also diagnosed as chronic 
hepatitis from the histopathological observation. In two dogs with HCA, non-neoplastic 
liver samples could not be taken. Fifty-eight of dogs with hepatobiliary disease in this 
study included 27 male (neutered, 17) and 31 female (neutered, 15) and the median age 
was 9.5 (range; 0.4 - 13.2) years. Breeds of the dogs were as follows: Toy poodle (n=10), 
Yorkshire Terrier, Mixed breed (n = 5 each), Chihuahua, Maltese, Miniature Dachshund, 
Shih Tzu (n = 3 each), American Cocker Spaniel, Pekingese, Pomeranian, Pug, Shetland 
Sheepdog, Shiba (n=2 each) and other 14 breeds (n=1 each). 
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Measurement of lipid and glycogen in the liver 
Lipid accumulation in hepatocyte was examined by ORO staining observed in 58 
dogs with various hepatobiliary diseases. In control dogs, small lipid droplets were 
observed in hepatocytes (Figure 5A). Lipid droplets in the hepatocytes of hepatobiliary 
cases were much larger in size and number than control dogs (Figure 5B), and some 
hepatocytes were ballooned because of lipid accumulation (Figure 5C). The median 
percentage of lipid area was 11.2% (range, 5.6-17.8%) in healthy control group, and a 
number of dogs with hepatobiliary diseases showed high percentage of lipid area. The 
number of dogs with higher percentage of lipid area than maximum value of control dogs 
were as follows: cPSS (9/19 [47.3%]), CH (11/14 [78.5%]), VH (2/3 [66.7%]), neoplastic 
area of HCC (1/9 [11.1%]), non- neoplastic area of HCC (8/9 [88.9%]), neoplastic area of 
HCA (6/8 [75.0%]), non- neoplastic area of HCA (5/6 [83.3%]), neoplastic area of CC 
(1/1 [100.0%]), non- neoplastic area of CC (1/1 [100.0%]) and GM (3/4 [75.0%]). The 
highest percentage of lipid area in dogs with hepatobiliary diseases was observed in a dog 
diagnosed as cPSS in this study (78.6%), The percentage of lipid area was significantly 
larger in CH (P=0.0168) and non- neoplastic area of HCC (P=0.0180) groups than 
control dogs (Figure 6A).  
Since tissue sample for measurement of glycogen weight could not be obtained 
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in six dogs (CH: n=3, non-neoplastic area of HCA: n=2, cPSS: n=1), glycogen weight 
was measured in 54 dogs. The median glycogen weight of control dogs was 25.3 mg/g 
(range, 7.7-37.8 mg/g). The number of dogs with glycogen amount larger than maximum 
value of control dogs (37.8mg/g) was as follows: cPSS (6/18 [33.3%]), CH (2/11 
[18.1%]), VH (3/3 [100.0%]) neoplastic area of HCC (2/9 [22.2%]), non-neoplastic area 
of HCC (2/8 [25.0%]), neoplastic area of HCA (2/8 [25.0%]), non- neoplastic area of 
HCA (2/6 [33.3%]), neoplastic area of CC (0/1 [0%]), non- neoplastic area of CC (1/1 
[100.0%]), GM (2/4 [50.0%]). No significant difference of glycogen weight was found 
between control and any diagnosis group. 
 
Evaluation of hepatocyte vacuolation 
Hepatocyte vacuolation of lipid and glycogen (Figure 4) were evaluated in 74 
samples from 58 dogs with hepatobiliary diseases and 7 samples of 7 control dogs (Table 
3) by HE staining. Only 1 sample of a control dogs showed mild glycogen and lipid 
vacuolation in all zones. Lipid accumulation was not observed in 35 of 74 samples 
(47.3%) from dogs with hepatobiliary disease. The number of samples that showed lipid 
vacuolation in each severity score was as follows: G1 (24/74, 32.4%), G2 (12/74, 16.2%), 
G3 (3/74, 4.1%). Zonal location of vacuolation was evaluated in the samples that showed 
vacuolation severity score of glycogen or lipid more than G1. There were 26 
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non-neoplastic samples except for samples of neoplastic area of hepatic tumors, and lipid 
vacuolation were observed in all zone in 21 of 26 samples (80.7%), localized to zone 1 
(periportal vacuolar changes) in 1 (3.8%) sample, localized to zone 3 (perivenular 
vacuolar changes) in 3 (11.5 %) samples, and in zone 2 to 3 in 1 (3.8%) sample. 
Glycogen vacuolation was not observed in 5 of 74 samples (6.8%) from the dogs with 
hepatobiliary disease. The number of samples that showed lipid vacuolation was as 
follows: G1 (26/74, 35.1%), G2 (30/74, 40.5%), G3 (13/74, 17.8%). There were 53 
non-neoplastic samples with glycogen vacuolation, and diffuse glycogen vacuolation was 
observed in all zone in 48 samples (90.6%), in zone 1 to 2 in 3 (5.6%) samples and 
involving zone 2 to 3 in 2 (3.8%) samples.  
The distribution of percentage of lipid area and glycogen weight in each 
vacuolation severity score was shown in Figure 7. There are some cases that showed high 
vacuolation severity score despite the actual lipid area percentage or glycogen amount 
was comparable with control dogs (5.6-17.8%). No significant difference of percentage 
of lipid area or glycogen weight was observed between any vacuolation severity score 
groups.  
 
Analysis between lipid/glycogen accumulation and clinical data in non-tumor diseases 
In 40 dogs with non-hepatic tumor diseases, percentage of lipid area was 
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compared to BCS (Figure 8). The percentage of lipid area tended to be higher when the 
dogs showed higher BCS, but no significant difference in percentage of lipid area was 
found between any BCS groups. (r =0.30, P=0.0712) 
Scatter plot of percentage of lipid area and concentration of triglyceride 
(reference range, 30-133 mg/dL) and total cholesterol (reference range, 111-312 mg/dL) 
was shown in Figure 9. A moderate correlation between percentage of lipid area and 
plasma triglyceride concentration was found (r =0.41, P=0.0141) and no significant 
correlation between percentage of lipid area and plasma total cholesterol concentration 
was found (r = 0.12, P = 0.134) (Figure 9B). There was no significant difference between 
percentage of lipid area or glycogen weight and serum total ALP activity, percentage and 
activity of each ALP isoenzyme, plasma ALT activity and plasma concentration of 
glucose, albumin and ammonia (data not shown). The glycogen weight of the liver was 
not significantly different between dogs with or without history of glucocorticoid drug 
administration (data not shown). Dogs with excess lipid accumulation showed higher 
serum CALP percentage and activity than dogs with normal lipid accumulation (Figure 
10A and B), however no significant difference was observed. There was no significant 
difference in serum CALP percentage and activity (Figure 10C and D) 
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Expression of lipid metabolism-associated gene in liver 
 The relative expression of lipid metabolism-associated genes was measured in 
8 healthy control dogs and 53 hepatobiliary diseases dogs. The number of each diagnosis 
groups was as follows; cPSS (n=16), CH (n=14), VH (n=3), HCC (n=9), HCA (n=7) and 
GM (n=4). Gene expressions of non-neoplastic area was not examined in one dog in 
HCA group because tissue sample could not be obtained. 
The relative expression of lipid metabolism-associated gene in each diagnoses 
groups was shown in Figure 11. There were significantly higher relative expression of 
LPL in CH (P=0.0072) group, DGAT1 in CH (P=0.0072), neoplastic (P=0.0120) and 
non-neoplastic (P=0.0069) area of HCC groups.  No significant difference was observed 
in relative expression of SREBP1c, PPARα, PPARγ, ChREBP1, LFABP, and DGAT2 
between healthy control group and any of the heaptobiliary diseases group. 
The non-neoplastic liver samples of hepatobiliary diseases were classified to 
normal lipid accumulation group (n=20) and high lipid accumulation group (n=32) 
compared to the upper limit of lipid area percentage in control group. Expression of lipid 
metabolism-associated genes in each groups and control group was shown in Figure 12. 
Dogs with excessed lipid accumulation showed significantly higher expression of 
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PPARα(P=0.0443), PPARγ (P=0.0027), LPL (P=0.0029) and DGAT1 (P=0.0012) than 
healthy control group. Normal lipid accumulation group showed significantly higher 
expression of PPARγ (P=0.0249) and DGAT1 (P=0.0240). No significant difference was 
observed in relative expression of SREBP1c, ChREBP1, LFABP, and DGAT2 between 
any groups. 
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DISCUSSION 
In this study, I showed excess lipid accumulation in the liver of dogs with 
hepatobiliary diseases. The liver tissues of CH and non-neoplastic area of HCC groups 
contained significantly more lipid than that of control groups. Considerable numbers of 
dogs in other disease groups also showed high lipid accumulation though no significant 
increase was observed. This result suggests that various hepatobiliary diseases would 
associate with alteration of lipid metabolism in canine hepatocyte.  
The condition of excess lipid accumulation in the liver is called fatty liver and is 
considered as risk factor for progressive fibrosis, cirrhosis and liver failure or 
hepatocellular carcinoma in human (Kikuchi et al., 2014; Takahashi and Fukusato, 2014). 
In this study, dogs in CH group showed significantly higher lipid accumulation than 
control dogs. It is conceivable that inflammatory stress induced lipid accumulation as 
previously reported in mouse (Ma et al., 2008) hepatic lipid accumulation relate to 
hepatitis development in dogs as well as in other species (Anstee and Goldin, 2006; 
Kikuchi et al., 2014; Takahashi and Fukusato, 2014). Liver of non-neoplastic area of 
HCC also showed significantly higher lipid accumulation in this study. HCC associated 
with vacuolar hepatopathy had been reported in Scottish Terriers (C. PEYRON, 2014; 
Cortright et al., 2014), though the content of the vacuole was unknown. From our result, 
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it can be hypothesized that vacuolar hepatopathy containing excess lipid might be 
associated with HCC development not only in Scottish terriers but also in other breeds, 
and therefore, higher lipid accumulation were observed around HCC tissue. 
The difference of lipid area percentages in liver tissue between cPSS group and 
control group was not significant. However, some cases showed markedly high 
percentage of lipid area. It has been reported that considerable percentage of dogs with 
cPSS accompanied liver steatosis (Baade et al., 2006; Lee et al., 2011), which is 
correspondent to our present result. Decrease of portal vein flow might induce canine 
hepatic steatosis in dogs with cPSS, because the steatosis was decreased after surgical 
attenuation of cPSS (Lee et al., 2011). The same mechanism might also induce lipid 
accumulation in the non-neoplastic liver area of tumor in this study since regional blood 
flow around tumor tissue tends to be decreased. In the present study, the percentage of 
dogs with lipid or glycogen vacuolation in all zones was higher than previous study 
(Sepesy et al., 2006), which investigates the hepatic vacuolation in hepatobiliary and 
non-hepatobiliary diseases. Diffuse hepatic vacuolation was observed in this study 
because the vacuolation was evaluated in only hepatobiliary diseases.  
Obesity is one of the risk factor of fatty liver in human (Arslan, 2014; Dietrich 
and Hellerbrand, 2014), and dogs with higher BCS also tend to show higher percentage 
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of lipid area in this study. However, the percentage of lipid area was not significantly 
different between any BCS groups. Further study with more objective evaluation of 
canine obesity, such as measurement of body fat mass, would provide more accurate 
relation between obesity and hepatic lipid accumulation in dogs. Significant and 
moderate correlation between percentage of lipid area and plasma triglyceride 
concentration was observed in this study. Fatty liver associated with hyperlipidemia had 
also been reported in human (Assy et al., 2000). In Schnauzer, vacuolar hepatopathy 
associated with hyperlipidemia had been reported (Guilford W.G. Center, 1996), though 
most of the dogs with hepatobiliary diseases used in this study showed normal 
concentration of triglyceride (Guilford W.G. Center, 1996). Further study using dogs with 
both hepatocyte vacuolation and high concentrations of plasma triglyceride would be 
needed. Serum CALP level of excess lipid accumulation group tented to be higher than 
normal lipid accumulation group in this study. The relationship between hepatic lipid 
accumulation and increase of serum CALP level was unclear and canine CALP was 
influenced by various factors, such as glucocorticoid drugs and endogenous hormones 
(Eckersall and Nash, 1983; Hoffmann and Dorner, 1975; Wellman et al., 1982). Further 
study is needed to reveal the mechanism of CALP increasing secondary to lipid 
accumulation in liver. 
I also evaluated the expression of lipid metabolism-associated genes in liver. 
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Expressions of PPARα, PPARγ, LPL, DGAT1 were elevated in dogs with excess lipid 
accumulation in the liver. Increased expression of PPARα and LPL were not observed in 
dogs with normal level of lipid accumulation. LPL is an enzyme contribute to hepatocyte 
incorporation of lipid, ant the expression is regulated by PPARγ (Schoonjans et al., 1996). 
High expression of LPL might be one of the reasons of excess lipid accumulation in liver. 
In contrast, PPARα is a transcription factor inducing gene expression related to 
beta-oxidation of fatty acids (Reddy, 2001). Since the pathway is accelerated when 
lipolysis is active, high expression of PPARα might be a result of lipid accumulation in 
the liver. Expression of PPARγ and DGAT1 were elevated in dogs with or without lipid 
accumulation in the liver. The reason for this result is unclear, however, both genes have 
stimulating effect on lipid lipogenesis in liver (Inoue et al., 2005; Nakamuta et al., 2005). 
Consistent expression of these genes might be related to induction of lipid accumulation 
in canine liver. 
No significant difference was observed in glycogen weight between any 
hepatobiliary disease groups in this study. It has been indicated that endogenous or 
exogenous glucocorticoid exposure would induce canine hepatic glycogen accumulation 
in the previous report(Fittschen and Bellamy, 1984; Rogers and Ruebner, 1977; Sepesy et 
al., 2006). Since serum glucocorticoid hormones were not measured in this study, it is not 
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clear whether high glycogen accumulation in this study were the result in increase of 
serum cortisol induced by stress associated with chronic illness. 
In this study, the vacuolation score determined by histology did not have 
correspondence with glycogen weight or percentage of lipid area percentage. Therefore, it 
would be difficult to estimate actual amount of glycogen or lipid in the liver from the 
observation of HE stained section. The discrepancy between the observation of HE 
staining and the actual amount of glycogen and lipid might be attributed to the 
intracellular edema or water, which is also a suspected component of hepatocyte 
vacuolation (Guilford W.G. Center, 1996; Rothuizen, 2006). 
In conclusion of this chapter, dogs with hepatobilially diseases tended to showed 
excess lipid accumulation in the liver and it was suggested that up-regulation of 
lipogensis would relate to canine excess lipid accumulation in liver. Moreover, dogs with 
excess lipid accumulation tended to show higher serum CALP level than dogs with 
normal lipid accumulation. The cause and effect of lipid accumulation in the liver for 
dogs is still unclear, so it is necessary to clarify the mechanism and effect of lipid 
accumulation for canine liver in further study. 
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Table 2. Primers used for quantitative polymerase chain reaction analysis 
  Gene Symbol  Forward Primer (5'-3')   Reverse Primer (5'-3')  Product Size(bp) 
SREBP1c TGGATTGCACATTCGAAGAC AGCTCATTGTGGCAGGAGAT 168 
PPARα CACAGACACGCTCTCACCAG 
 
AAGAAACCCTTGCAGCCTTC 174 
PPARγ GAAGGATGCAAGGGCTTCTT CCAAACCTGATGGCATTATGA 162 
ChREBP1 GATGCCTATGTGGGCAATG 
 
GGTAGCTGGTGAAGAAATCTGA 132 
LFABP TCAAGGCAGTGGTTCAGATG TGGTATTGGTGATCACATCG 108 
LPL CTACCGGTGCAACTCAAAGG 
 
GGAAGACTTTGTAAGGCATCTGA 161 
DGAT1 TGGTGATGCTGATCTTGAGC TGGTGATGCTGATCTTGAGC 150 
DGAT2 CTTCCTTGTGCTTGGAGTGG 
 
GACCTCCTGCCACCTTTCTT 
 
135 
HMBS TCACCATCGGAGCCATCT 
 
GTTCCCACCACGCTCTTCT 
 
112 
RPL13A GCCGGAAGGTTGTAGTCGT 
 
GGAGGAAGGCCAGGTAATTC 
 
87 
RPL32 TGGTTACAGGAGCAACAAGAAA GCACATCAGCAGCACTTCA  100 
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Table 3. Summary of severity score of hepatic vacuoles change 
 
    Lipid  Glycogen 
    
Severity score of 
 vacuoles change 
 Severity score of 
 vacuoles change 
Category n G0 G1 G2 G3  G0 G1 G2 G3 
Healthy control 7 6 1 0 0  6 1 0 0 
PSS 19 10 8 1 0  1 9 8 1 
CH 14 7 5 1 1  1 4 7 2 
VH 3 3 0 0 0  0 1 2 0 
HCC (neoplastic area) 9 3 4 1 1  1 2 3 3 
HCC (non-neoplastic area) 9 6 0 3 0  0 5 3 1 
HCA (neoplastic area) 8 2 2 3 1  1 2 3 2 
HCA (non-neoplastic area) 6 2 2 2 0  1 2 0 3 
CC (neoplastic area) 1 0 0 1 0  0 0 1 0 
CC (non-neoplastic area) 1 0 1 0 0  0 0 1 0 
GM 4 2 2 0 0  0 1 2 1 
PSS: portosystemic shunt, CH: chronic hepatitis, VH: vacuolar hepatopathy, HCC: 
hepatocellular carcinoma, HCA: hepatocellular adenoma,CC: cholangiocarcinoma, GM: 
gallbladder mucocele. 
G0:0%, G1:1~33%, G2:34~66%, G3:66%~ of hepatocyte vacuolated 
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Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
Histological feature of canine liver vacuolation in dogs with chronic hepatitis. HE 
staining. (A) Discrete clear hepatocyte vacuolation which is considered to contain lipid 
(arrows) and (B) cytoplasmic rarefaction which is considered to contain glycogen. bar = 
50µm.  
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Figure 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dot plot of (A) lipid area percentage and (B) glycogen weight in each diagnosis group. 
cPSS: portosystemic shunt, CH: chronic hepatitis, VH: vacuolar hepatopathy,  HCC: 
hepatocellular carcinoma, HCA: hepatocellular adenoma, CC: cholangiocarcinoma, GM: 
gallbladder mucocele. ＊P < 0.05 , Steel test 
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Figure 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dot plot of (A) lipid area percentage and (B) hepatic glycogen weight in each lipid 
vacuolation score group dogs with hepatobilially diseases.  
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Figure 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dot plot of lipid area percentage in each body conditioning score group of dogs with 
non-tumor hepatobilially disease. 
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Figure 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scatter plot of percentage of lipid area and (A) plasma triglyceride concentration or (B) 
total cholesterol concentration in dogs with non-tumor hepatobiliary diseases. Grey area 
indicates the reference range of triglyceride or total cholesterol concentration in dogs. 
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Figure 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dot plot of CALP (A) percentage and (B) activity in dogs with hepatobiliary diseases 
accumulated with normal level of lipid and high level of lipid in liver tissue. Dot plot of 
CALP (C) percentage and (D) activity in dogs with hepatobiliary diseases accumulated 
with normal level of glycogen and high level of glycogen in liver tissue. 
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Figure 11 
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Relative expression of (A) SREBP1c, (B) PPARα, (C) PPARγ, (D) ChREBP1, (E) LPL, 
(F) LFABP, (G) DGAT1 and (H) DGAT2 in each diagnosis group: (1) healthy control (2) 
cPSS, (3) CH, (4) VH, (5) HCC (neoplastic area), (6) HCC (non-neoplastic area), (7) 
HCA (neoplastic area), (8) HCA (non-neoplastic area) and (9) GM. ＊P < 0.05 , Steel test 
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Figure 12 
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Relative expression of (A) SREBP1c, (B) PPARα, (C) PPARγ, (D) ChREBP1, (E) LPL, 
(F) LFABP, (G) DGAT1 and (H) DGAT2 in each diagnosis group: (1) healthy control 
dogs or dogs with hepatobiliary diseases accumulated with (2) normal level of lipid and 
(3) high level of lipid in liver tissue. ＊P < 0.05 , Steel test 
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Chapter 3 
Increase of serum alkalinephosphatase activity in 
dogs intravenously administrated with fat emulsion 
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ABSTRACT 
In dogs, excess lipid accumulation causes hepatic vacuolation that is frequently 
observed with high serum ALP activity. In adult dogs, two ALP isozenzymes, liver ALP 
(LALP) and corticosteroid-induced ALP (CALP) can be detected in serum. In our 
previous study, dogs with hepatobiliary diseases accompanied with hepatic lipid 
accumulation showed higher serum ALP activity and increased expression of lipid 
synthesis associated genes. In Schnauzer, hyperlipidemia-associated vacuolar 
hepatopathy was reported with increased plasma triglyceride, cholesterol and ALP 
activity. However, since serum ALP activity is easily influenced by hepatocyte disorder 
and cholestasis of various reasons, direct relation between lipid metabolism and ALP 
activity should be examined. The objective of this study is to investigate the change of 
serum ALP activity, gene expression of ALP in liver, and alteration of lipid metabolism 
including hepatic lipid accumulation and gene expression when fat emulsion is 
experimentally induced to dogs by intravenous administration. 
Four dogs were intravenously administrated fat emulsion corresponding to 50 % 
of daily energy requirement over 4.5 hours. Lipid accumulation and histological changes 
of the liver, plasma activities of liver enzymes (ALT, GGT, GOT, LALP and CALP), 
concentrations of triglyceride and total cholesterol and mRNA expressions of LALP, 
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CALP and 8 lipid metabolism-associated genes (SREBP1c, PPARα, PPARγ, ChREBP1, 
LPL, LFABP, DGAT1 and DGAT2) were evaluated during fat emulsion administration 
experiment. After 4 days of lipid emulsion administration, 2 of 4 dogs showed increased 
hepatic lipid accumulation and all of 4 dogs had histologically enlarged hepatocyte. 
Activities of serum total ALP, LALP and CALP were increased gradually from day 0 to 
day 4 in all dogs, while other blood biochemical values did not change. Expression of 
CALP mRNA in the liver was increased in two dogs that showed increased lipid 
accumulation in liver. Expression of PPARγ mRNA of all dogs was increased on day 5 
and 18 than day 0, however, expression of other 7 lipid metabolism-associated genes 
were not notably changed. 
In the present study, intravenous fat emulsion administration induced increased 
serum ALP activity, expression of LALP and PPARγ. Moreover, 2 of 4 dogs showed 
increased lipid accumulation and CALP expression after fat emulsion administration. 
These results suggest that lipid overload would affect to activity and expression of ALP 
isoenzymes, especially CALP expression would relate to lipid metabolism disorder in 
hepatocyte. 
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Introduction 
In dogs, there are some abnormalities of lipid metabolism, such as 
hypertriglyceridemia, hypercholesterolemia and excess lipid accumulation in liver. 
Excess lipid accumulation in the liver is recognized as hepatic vacuolation in HE stained 
section and can be observed in congenital portosystemic shunt (Hunt et al., 2014; Lee et 
al., 2011), nodular hyperplasia (Fabry et al., 1982) and other various hepatobiliary 
diseases as described in chapter Ⅱ in this thesis. Although the mechanism to induce 
lipid accumulation in canine liver is not clear in the light of lipid metabolism, 
hyperlipidemia-associated vacuolar hepatopathy has been reported in Schnauzer together 
with increased plasma triglyceride, cholesterol and ALP activity (Guilford W.G. Center, 
1996). 
Two ALP isozenzymes, liver ALP (LALP) and corticosteroid induced ALP 
(CALP) is produced in canine liver (Sanecki et al., 1987). CALP isoenzyme is unique to 
dogs, and induced by endogenous and exogenous corticoid hormone stimulation 
(Fittschen and Bellamy, 1984; Syakalima et al., 1997a; Wellman et al., 1982), or various 
hepatobiliary diseases as shown in chapter Ⅰ in this thesis. It has been reported that 
dogs with excess lipid accumulation showed higher serum CALP activity and percentage 
compared to dogs with normal lipid accumulation in the liver when studied with naturally 
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occurring hepatobiliary cases. Since hepatobiliary diseases would influence serum ALP 
activity, the direct relationship between high serum CALP activity and hepatic lipid 
accumulation is still unclear. No study evaluating the change of serum ALP isoenzymes 
after experimentally inducing fatty liver in dogs had been reported so far. The aim of this 
study is to experimentally inducing fat emulsion to dogs for evaluating the change in 
hepatocyte lipid metabolism including hepatic lipid accumulation condition and serum 
hepatic enzyme activities including ALP isoenzymes.  
In terms of lipid metabolism associated gene expression in dogs, it has been 
reported that the mRNA expression of lipogensis associated genes, SREBP1 and LFABP, 
was increased in liver of obese dogs (Kabir et al., 2005). To determine whether lipid 
metabolism related gene expression is altered in dogs with in liver of dogs with fat 
emulsion administration, I also measured 8 genes involved in lipid metabolism (Jump et 
al., 2013; Musso et al., 2009; Nguyen et al., 2008) in the liver tissue. The eight genes 
included 4 transcription factors which regulate hepatic lipid metabolism: sterol response 
element binding protein-1c (SREBP-1c), carbohydrate response element binding protein 
(ChREBP1), the peroxisome proliferator-activated receptor α (PPARα) and PPAR γ. I 
also measured expression of the gene coding lipid metabolism-associated enzymes, 
lipoprotein lipase (LPL) which hydrolyze lipid for uptake in hepatocyte, liver fatty acid 
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binding protein (LFABP) which delivery fatty acids in hepatocyte, diacylglycerol 
acyltransferase 1 (DGAT1) and DGAT2, which catalyzes the final step of triglyceride 
synthesis. 
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Materials and Methods 
Animals 
Clinically healthy 4 beagle dogs (castrated male: n=3, spayed female: n=1) 
were used in this study. The procedure was conducted in compliance with the guidelines 
of the Animal Care Committee of the Graduate School of Agricultural and Life Sciences, 
the University of Tokyo (approval number; 924 approved, 2014). The mean body weight 
(BW) was 10.4 kg (range, 9.7-10.7) and the mean age was 5.8 years (range, 3.2 -7.8).  
 
Fat emulsion administration, blood biochemical analysis and sample collection 
During the study, all 4 dogs were fed with a standard food corresponding to daily 
energy requirement (DER). DER was calculated as follows (Pointer et al., 2013): 
DER=1.8×70×BW0.75. Fat emulsion (Intralipos, Ohtsuka Pharmaceutical, Ltd, Tokushima, 
Japan) corresponding to 50% of DER was administrated intravenously over 4.5 hours 
each day. The day that the fat emulsion administration has been started was defined as 
day 1, and the administration was repeated from day 1 to day 4. Blood sample were 
drawn from jugular vein at 0, 4.5 and 9 hours after the beginning of fat emulsion 
administration. Body weight was measured everyday before lipid emulsion 
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administration. Plasma activity of ALT, GGT and GOT, serum total ALP activity and 
concentration of triglyceride and total cholesterol were measured by automatic blood 
chemistry measurement equipment (DRI-CHEM, Fujifilm Medical Co., Japan). 
Percentages of ALP isoenzymes (LALP, CALP and BALP) were measured by 
electrophoresis and colour densitometry analysis (LSI Medience, Tokyo, Japan). The 
activity of each isoenzyme was calculated from the percentage and total ALP activity 
(Itoh et al., 2002). Serum concentration of total bile acid was measured by the enzyme 
method (Monolis, Inc. Tokyo, Japan) on day 0 and 5. Ultrasound-guided biopsies were 
performed by using 14G Tru-cut type needles (Argon Medical Devices, TX, USA) on day 
0, day 5 and 18.  
 
Evaluation of liver tissue samples 
All liver tissue samples were fixed in 10% formalin, processed and paraffin 
embedded, cut into sections, and stained with hematoxylin and eosin (HE) for 
histopathological evaluation. The severity of hepatocyte vacuolation was scored from G0 
to G3 (G0 or absent = 0% of hepatocyte vacuolated, G1 or mild <33% of hepatocyte 
vacuolated, G2 or moderate 34-66% of hepatocyte vacuolated, G3 or severe >67% of 
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hepatocyte vacuolated) (Kleiner et al., 2005a). The number of hepatocytes was counted in 
5 separate, randomly selected ×400 fields, and the mean number was calculated.  
Another biopsy sample was placed into a Tissue-Tek container, which was then 
filled with Tissu-Tek OTC compound gel (Sakura Finetek, Torrance, CA). The sample 
was then frozen rapidly, being cut into 6µm slices, and then stained for lipid using a 
standard Oil Red O protocol (Hunt et al., 2014; Lee et al., 2011). The percentage of the 
area occupied by Oil Red O-stained lipid droplets in the liver tissue was calculated using 
Image J (http://rsbweb.nih.gov/ij/), in 5 separate, randomly selected ×200 fields(Liu et al., 
2014). 
 
RNA Extraction 
Total RNA was extracted from the liver samples by using RNAspin Mini RNA 
Isolation Kit (GE Healthcare). The extracted RNA was then treated with DNase I 
(Invitrogen, Carlsbad, CA) and reverse-transcribed with a PrimeScript RT reagent kit 
(Takara Bioscience, Tokyo, Japan) according to the manufacturer’s protocol.  
 
Quantitative Polymerase Chain Reaction Analysis  
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Expression of LALP, CALP and 8 lipid metabolism-associated genes were 
quantified by real-time RT-PCR: The 8 lipid metabolism-associated gene were SREBP1c, 
PPARα, PPARγ, ChREBP1, LPL, LFABP, DGAT1 and DGAT2. Three genes, HMBS, 
RPL13A and RPL32, were included as internal controls. Gene expression was quantified 
in triplicate samples using the Thermal Cycler Dice Real-Time System (Takara Bio Inc, 
Tokyo, Japan) with THUNDERBIRD SYBR qPCR Mix (Toyobo Co. Ltd, Osaka, Japan) 
according to the manufacturer’s instructions. Primers were designed using Primer 3 
(http://primer3.sourceforge.net/) or were selected by referring to previous publications 
(Peters et al., 2007). The sequences of the primer pairs used were shown in Table 4.  
Initial incubation at 95℃ for 15 seconds was followed by 40 polymerase chain 
reaction (PCR) cycles consisting of denaturation at 95 ℃  for 5 seconds and 
annealing/elongation at 60℃ for 1 minute. The final denature was carried out for 15 
seconds at 95℃ , followed by the melting curve reaction consisting of a gradual 
temperature increase from 60℃ to 90℃.  
The threshold cycle (Ct value) was determined using the second derivative 
maximum method. Before the samples were quantified, standard curves of the relative 
starting amount versus the Ct value were constructed using pooled liver cDNA. The 
amplification efficiency of each reaction was within 80% to 120%. The dissociation 
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curve was confirmed to have a single peak in each experiment and the PCR products 
were confirmed to be in agreement with their theoretic sizes by using agarose gel 
electrophoresis. The quantity of each transcript was determined by comparing the relative 
amount of the sample mRNA to that of RPL13A, RPL32 and HMBS mRNA using the 
ratio of mean Ct values (Peters et al., 2007). Relative gene expression was calculated as 
previously described. 
 
Statistical analysis  
Wilcoxon signed-rank test was used to test for significant differences in each 
biochemical parameters and mRNA expression between each time points. P < 0.05 was 
considered significant for the remaining statistical analysis in the present study. 
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Result 
Lipid accumulation in liver tissue and histological evaluation 
Plasma triglyceride concentration was changed rapidly by intravenous fat 
emulsion administration; markedly increased after administration and decreased to 
reference range 4.5 hour after the end administration. The maximum value of triglyceride 
concentration after fat emulsion administration was decreased day by day (Figure 13). 
After 4 days of lipid emulsion administration, 2 of 4 dogs showed increased 
percentage of lipid area evaluated by ORO staining (Figure 14). In these 2 dogs (dog 1 
and 2), the percentage of lipid area was kept high on day 18 (Figure 14E). By histological 
evaluation in HE sections (Figure 15), 2 of 4 dogs showed mild lipid vacuolation in day 0. 
The severity of one dog was decreased on day 5 and the severity of the other dog was 
kept on day 5. Glycogen vacuolation was observed in all of the 4 dogs on day 0, 5 and 18. 
The glycogen vacuolation severity score became more severe at day 5 compared to day 0 
in 3 of the 4 dogs, and retained in 2 of 3 dogs after the fat emulsion administration period, 
on day 18 (Table 5). The mean number of hepatocyte per field in each time point was as 
follows, day 0 (median 70.4, range 67.4-75.8), day 5 (median 45.7, range 42.2-46.4) and 
day 18 (median 48.2, range 47.8-57.4). The mean number of hepatocyte per field was the 
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smallest on day 5, indicating that hepatocyte of these dogs were most severely swelled on 
day 5. However, there was no significant difference in the mean number of hepatocyte 
between day 0, 5 and 18. 
 
Changes in blood biochemical value and gene expression of ALP isoenzyme in liver 
tissue 
Total serum ALP activity was gradually increased in all of the 4 dogs exceeding 
the upper limit of reference range (47-254 U/L) on day 3 (Figure 16A). LALP and CALP 
activity was also increased (Figure 16B and C), but no significant difference in total ALP, 
LALP and CALP activity was observed between on day 0 and day 1, 2, 3 and 4 in this 
study. Plasma activity of GPT, GGT and GOT and concentrations of total cholesterol was 
not changed during this study (data not shown). Serum TBA concentration was within the 
reference range on day 0 and day 5 in 3 dogs, while beyond the normal range in 1 dog 
(21.8 nmol/mL, reference range: 0.1-10.0 nmol/mL) on day 0. Further, the gene 
expression of ALP isoenzyme genes was evaluated by RT-PCR. LALP expression was 
increased in all of 4 dogs on day 18 compared to day 0 (Figure 17A), and CALP 
expression was increased in 2 of 4 dogs (dog 1 and 2) on day 5 compared to day 0. The 2 
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dogs (dog 1 and 2) were the identical dogs that showed excess lipid accumulation in liver 
(Figure 17B).  
 
Expression analysis of lipid metabolism-associated genes in liver tissue 
In the relative expression of lipid metabolism-associated genes, PPARγ is 
increased on day 5 and 18 compared to day 0 (Figure 18C). The expression of the other 
lipogenesis-associated genes was not changed markedly from day 0 to 18 (Figure 18A, B 
and D-H).  
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Discussion 
In the present study, intravenous fat emulsion administration induced increased 
serum ALP activity and increased gene expression of LALP and PPARγ in liver. Excess 
lipid accumulation and increased CALP expression in liver was also observed in 2 of 4 
dogs at the end of fat emulsion administration for 4 days. 
Two dogs showed increased hepatic lipid accumulation and the other 2 dogs did 
not show notable lipid accumulation in this study. Plasma lipid might also be absorbed to 
adipose tissue (Tilg and Moschen, 2010) as well as to hepatocytes, possibly at higher 
rates in the latter 2 cases. There might be an individual difference in lipid distribution. 
Although increased lipid accumulation was observed in only 2 of 4 dogs, hepatocyte 
swelling secondly to hepatocyte vacuolation was observed in all of 4 dogs on day 5 and 
day 18. The component of the hepatocyte vacuole in the 2 dogs without liver lipid 
accumulation would be expected as glycogen, intracellular edema or water (Guilford 
W.G. Center, 1996; Rothuizen, 2006). Since dogs were taken calorie more than DER by 
diet and fat emulsion in present study and intravenously induced fat emulsion would be 
spend firstly as energy, carbohydrate in diet, which corresponds to surplus calories, 
would be metabolized and stored as glycogen in hepatocyte. Although the mechanism of 
the accumulation of these contents after fat emulsion administration is unclear, other 
method for inducing hepatic lipid accumulation, such as high fat diet feeding (Inoue et al., 
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2005) would be needed to study about canine hepatic lipid accumulation. 
Serum ALP activity was increased gradually between day 1 to day 5, and 
decreased on day 18. Although serum TBA concentration was not increased on day 5, 
swelling of hepatocyte secondary to fat emulsion administration might have caused 
microenvironmental cholestasis resulting in increase of plasma LALP activity. Indeed, 
LALP expression is indicated to be up regulated by cholestasis in other species (Khan et 
al., 1998; Suzuki et al., 2006). After the hepatocyte swelling subsided, expression of 
LALP mRNA was increased on day 18. Nevertheless, serum LALP activity was 
decreased on day 18, indicating that the change of serum LALP activity is rather 
influenced by cholestasis than the change of production in liver.  
Relative gene expression of CALP was increased on day 5 than day 0 in the two 
dogs that showed higher hepatic lipid accumulation in the liver on day 5. CALP is coded 
by intestinal ALP (IALP) gene in canine liver (Sanecki et al., 1987; Wellman et al., 1982) 
different from LALP, which is coded by the tissue nonspecific ALP gene together with 
BALP (Hoffmann and Dorner, 1975; Wellman et al., 1982). IALP gene is expressed in 
intestinal mucosa and plays a role in regulating fat absorption (Lalles, 2010). Since it has 
been reported that high fat feeding induced increased IALP expression in rat liver 
(Goseki-Sone et al., 1996), canine CALP expression might also be up-regulated in liver 
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associated with hepatic lipid metabolism. 
In all of 4 dogs, relative gene expression of PPARγ was elevated after fat 
emulsion administration: the highest on day 5 and kept higher on day18 than day 0. 
Expression of PPARγ has also been up-regulated in mouse fed with high fat diet in the 
previous study. The elevation of canine PPARγ expression might be induced by 
triglyceride administration in this study. PPARγ has an important role in hepatic lipid 
metabolism, regulating the expression of LPL (Nakamura et al., 2014). However, LPL 
expression did not change in this study in spite of increased PPARγ expression. Increased 
expression of PPAR alone would not contribute to activation of lipogenesis. Compared to 
dogs with spontaneous hepatobiliary diseases, the degree of hepatic lipid accumulation 
was mild. Fat emulsion administration in this study might be too short and rapid to alter 
the expression of multiple lipid-metabolism associated genes.  
In the present study, increased serum ALP activity, expression of LALP and 
PPARγ was observed by intravenous fat emulsion administration. Moreover intravenous 
fat emulsion administration for dogs partly induced increase in liver lipid area, CALP 
isoenzymes expression. The mechanisms of hepatic lipid accumulation to induce serum 
CALP activity are still unclear. Future study using improved fatty liver dog model would 
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be helpful to clarify the mechanism of CALP isoenzyme expression induced by hepatic 
lipid accumulation. 
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Table 4. Primers used for quantitative polymerase chain reaction analysis 
  Gene Symbol  Forward Primer (5'-3')   Reverse Primer (5'-3')  Product Size(bp) 
LALP TCAAACCGAGACACAAGCAC GGGTCAGTCACGTTGTTCCT 
 
172 
CALP CACACCTCATGGGCCTC 
 
GCCTCCTTCCACAAAGAGGTA 224 
SREBP1c TGGATTGCACATTCGAAGAC AGCTCATTGTGGCAGGAGAT 168 
PPARα CACAGACACGCTCTCACCAG 
 
AAGAAACCCTTGCAGCCTTC 174 
PPARγ GAAGGATGCAAGGGCTTCTT CCAAACCTGATGGCATTATGA 162 
ChREBP1 GATGCCTATGTGGGCAATG 
 
GGTAGCTGGTGAAGAAATCTGA 132 
LFABP TCAAGGCAGTGGTTCAGATG TGGTATTGGTGATCACATCG 108 
LPL CTACCGGTGCAACTCAAAGG 
 
GGAAGACTTTGTAAGGCATCTGA 161 
DGAT1 TGGTGATGCTGATCTTGAGC TGGTGATGCTGATCTTGAGC 150 
DGAT2 CTTCCTTGTGCTTGGAGTGG 
 
GACCTCCTGCCACCTTTCTT 
 
135 
HMBS TCACCATCGGAGCCATCT 
 
GTTCCCACCACGCTCTTCT 
 
112 
RPL13A GCCGGAAGGTTGTAGTCGT 
 
GGAGGAAGGCCAGGTAATTC 
 
87 
RPL32 TGGTTACAGGAGCAACAAGAAA GCACATCAGCAGCACTTCA  100 
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Table 5. Lipid and glycogen vacuolation severity score and mean number of hepatocyte 
  Vacuolation severity score (Lipid) Vacuolation severity score (Glycogen) 
  Day 0 Day 5 Day 18 Day 0 Day 5 Day 18 
dog 1 1 0 0 1 1 2 
dog 2 1 1 0 1 2 2 
dog 3 0 0 0 1 2 2 
dog 4 0 0 0 1 2 1 
 0:0%, 1:1~33%, 2:34~66%, 3:66%~ of hepatocyte vacuolated 
 * The mean number of hepatocyte counted in 5 separate, randomly selected ×400 fields 
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Figure 13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change in plasma triglyceride concentration after fat emulsion administration. Plasma 
triglyceride concentration was measured before fat emulsion administration, immediately 
after 4.5 hour administration of fat emulsion and 4.5 hour after the end of fat emulsion 
administration each day from day 0 to day 4. Plasma triglyceride concentration was also 
measured on day 5. 
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Figure 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 85 
Frozen section of canine liver stained by Oil Red O staining. Liver section of dog 1 on 
(A) day 0 and (B) day 5. Liver section of dog 3 on (C) day 0 and (D) day 5. bar = 100µm. 
(E) Transition of lipid area percentages in 4 dogs after lipid emulsion administration. 
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Figure 16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Changes in serum (A) total ALP activity, (B) LALP activity and (C) CALP activity in 4 
dogs after fat emulsion administration. Analysis was performed before fat emulsion 
administration, immediately after 4.5 hour of fat emulsion administration and 4.5 hour 
after the end of fat emulsion administration each day from day 0 to day 4. Measurement 
was also performed on day 5 and day 18. 
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Figure 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relative gene expression of (A) LALP and (B) CALP in the liver of 4 dogs administrated 
with fat emulsion. Data of mRNAs were expressed relative to the geometric mean of 
three reference genes and were plotted as the result of calculation from the ratio of the 
mean relative expression on day 0 
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Figure 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 90 
Relative gene expression of 8 lipid metabolism-associated genes in the liver of 4 dogs 
administrated with fat emulsion. Data of mRNAs were expressed relative to the 
geometric mean of three reference genes and were plotted as the result of calculation 
from the ratio of the mean relative expression on day 0. 
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Conclusion 
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The studies in this thesis were carried out to investigate the activity of serum 
ALP isoenzymes as well as the actual effects and mechanism of hepatic lipid 
accumulation in dogs with hepatobiliary diseases.  
In chapter 1, serum ALP isoenzymes were measured in dogs with 
hepatobiliary disease without a history of glucocorticoid drug administration. 
Hyperadrenocorticism (Teske et al., 1989; Wellman et al., 1982) and glucocorticoid 
administration was considered to have increased the serum CALP level (Dorner et al., 
1974; Syakalima et al., 1997a). However, the results reported in Chapter 1 showed that 
the canine serum CALP level was increased regardless of glucocorticoid administration 
or baseline of serum cortisol concentration in various hepatobiliary diseases. Although 
elevation of serum LALP activity is common in dogs with hepatobiliary diseases, the 
contribution of CALP to the total ALP activity needs to be considered even in conditions 
of apparent hepatobiliary diseases. Furthermore, dogs with vacuolar hepatopathy without 
the effects of endogenous/exogenous cortisol showed markedly high serum CALP. 
Glucocorticoid hormones were considered to have induced hepatocyte vacuolation 
secondary to glycogen accumulation and serum CALP elevation in previous studies 
(Dorner et al., 1974; Syakalima et al., 1997a). The result reported in chapter 1 suggests 
that the accumulation of substances other than glycogen could induce the vacuolar 
change and CALP production in dogs.  
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In chapter 2, the specific amount of hepatic lipids or glycogen accumulated in 
dogs with various hepatobiliary diseases to the activity of each serum ALP isoenzyme 
were assessed and compared. Dogs with hepatobiliary disease with a larger lipid 
accumulation than control dogs tended to show elevated serum CALP levels. Therefore, 
it was suggested that hepatic lipid accumulation was partly associated with serum CALP 
elevation. Because hepatobiliary diseases could influence serum ALP activity, a clinically 
healthy dog model of excess lipid accumulation is needed to clarify the relationship 
between canine serum CALP activity and hepatic lipid accumulation. This study also 
revealed that excess hepatic lipid accumulation occurs widely in dogs with hepatobiliary 
diseases. In humans, fatty liver was confirmed to develop into hepatitis, cirrhosis, and 
hepatocellular carcinoma (Dietrich and Hellerbrand, 2014; Musso et al., 2009). In this 
study, the liver of dogs with chronic hepatitis and non-neoplastic regions of 
hepatocellular carcinoma showed significantly higher lipid accumulation than that of 
control dogs did. It is likely that the clinical state of canine hepatic lipid accumulation is 
similar to that of humans, but the determination of the effect of lipid accumulation on 
canine hepatic diseases was beyond the scope of this thesis. Further studies on the 
progression of hepatobiliary diseases are required to reveal the impact of canine hepatic 
lipid accumulation. Moreover, gene expression analysis revealed that dogs in the excess 
lipid accumulation group showed increased expression of de novo lipid synthesis 
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associated genes (PPARγ, LPL, and DGAT1). These results suggest that increased 
hepatic lipogenesis induced excess lipid accumulation in dogs. Increased expression of 
PPARγwas also observed in the fatty liver of humans (Chao et al., 2000) and, therefore, 
canine hepatic lipid accumulation might have similar pathophysiology to human fatty 
liver disease. In future, studies focused on the mechanisms of canine hepatic lipid 
accumulation would show the usefulness and versatility of the dog in the fatty liver 
model animal, and contribute to developing new treatments for dogs with excess lipid 
accumulation. 
In Chapter 3, induction of excess hepatic lipid accumulation was attempted by 
intravenously administering a fat emulsion, and the relationship between hepatic lipid 
accumulation and the activity as well as hepatic expression of serum ALP isoenzymes 
was verified. CALP expression and the amount of lipid accumulation were increased in 2 
of the 4 dogs after fat emulsion administration. This result suggests that CALP expression 
was induced by lipid accumulation in the hepatocytes. All 4 dogs showed increased total 
serum ALP activity associated with hepatocyte swelling secondary to fat emulsion 
administration and, therefore, the relationship between the serum CALP activity and 
expression induced by lipid accumulation is still unclear. Moreover, the analysis of lipid 
metabolism-associated gene expression showed that only that of PPARγ was increased 
by fat emulsion administration regardless of the difference in hepatic lipid accumulation. 
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These results indicate that the activation of lipogenesis was not induced by PPARγ 
expression alone. Further studies using a physiological canine model of fatty liver (e.g., 
long-term feeding with a high-fat diet) would be useful for investigating the mechanisms 
of hepatic lipid accumulation and multiple factors assumed to be involved in lipid 
metabolism in dogs.  
In conclusion, the series of studies reported in this thesis showed new 
findings of mechanisms associated with CALP increase. The results reported in Chapter 1 
showed that serum CALP activity was increased in dogs with various hepatobiliary 
diseases regardless of glucocorticoid drug administration while results reported in 
Chapters 2 and 3 suggest that serum CALP increase was at least partly related to hepatic 
lipid accumulation in dogs. In future studies, it would be necessary to clarify the 
relationship between factors inducing CALP expression in hepatocyte and the genes 
associated with lipid accumulation. Furthermore, results described in Chapter 2 revealed 
that hepatic lipid accumulation occurred more extensively in dogs with hepatobiliary 
diseases, especially hepatitis and hepatocellular carcinoma than it did in healthy dogs. 
Increased expression of PPARγ, a lipogenesis-associated gene, was observed in the liver 
of dogs with excess lipid accumulation in the results described in chapters 2 and 3, and 
this would be an interesting gene to investigate further in an animal model of fatty liver. 
It was reported that lipid accumulation in hepatocyte develops into hepatitis and 
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hepatocellular carcinoma by inflammatory cytokine induction in human. In future, it 
would be expedient to investigate the effect of hepatic lipid accumulation on the 
inflammatory condition, immune state, and prognosis of dogs with hepatobiliary diseases. 
Further studies are also needed to examine the usefulness of diet and drug treatment in 
reducing lipid accumulation in the canine liver.  
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